New York State Common Retirement Fund grew its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 1.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 387,492 shares of the company’s stock after buying an additional 4,000 shares during the quarter. New York State Common Retirement Fund owned approximately 0.31% of Ionis Pharmaceuticals worth $19,646,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Parallel Advisors LLC lifted its holdings in shares of Ionis Pharmaceuticals by 62.8% during the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after purchasing an additional 800 shares during the period. Aviva PLC acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth $10,187,000. Allen Investment Management LLC lifted its holdings in shares of Ionis Pharmaceuticals by 64.7% during the second quarter. Allen Investment Management LLC now owns 15,652 shares of the company’s stock worth $796,000 after purchasing an additional 6,147 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Ionis Pharmaceuticals by 21.4% during the second quarter. Russell Investments Group Ltd. now owns 20,077 shares of the company’s stock worth $1,021,000 after purchasing an additional 3,538 shares during the period. Finally, Bank of Nova Scotia acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth $1,526,000. 91.57% of the stock is currently owned by hedge funds and other institutional investors.

In other news, COO B Lynne Parshall sold 16,118 shares of the company’s stock in a transaction dated Wednesday, October 18th. The shares were sold at an average price of $65.00, for a total transaction of $1,047,670.00. Following the transaction, the chief operating officer now owns 33,526 shares in the company, valued at $2,179,190. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stanley T. Crooke sold 15,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $52.00, for a total transaction of $780,000.00. Following the transaction, the chief executive officer now owns 43,014 shares in the company, valued at approximately $2,236,728. The disclosure for this sale can be found here. In the last 90 days, insiders sold 123,886 shares of company stock worth $7,098,315. 2.13% of the stock is owned by company insiders.

A number of equities analysts have recently commented on IONS shares. BidaskClub upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, December 7th. BMO Capital Markets reiterated an “outperform” rating and set a $69.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Barclays dropped their target price on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating on the stock in a report on Thursday, September 21st. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, November 9th. Finally, Needham & Company LLC restated a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $50.31.

Ionis Pharmaceuticals, Inc. (IONS) opened at $53.57 on Thursday. The stock has a market cap of $6,657.84, a price-to-earnings ratio of 355.67 and a beta of 2.85. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $37.26 and a fifty-two week high of $65.51.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/new-york-state-common-retirement-fund-boosts-holdings-in-ionis-pharmaceuticals-inc-ions/1762886.html.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.